The Developmental Research Program is designed to provide funding to initiate promising translational studies with a focus on breast cancer. High priority will be given to projects that will generate clinically-relevant hypotheses aimed at reducing the incidence, morbidity or mortality of breast cancer or improving the quality of life of patients with breast cancer. At least annually, proposals for innovative translational research in breast cancer will be solicited throughout all institutions in the Texas Medical Center. It is anticipated that some applicants will be without extensive experience in preparing successful research proposals;therefore, the Director and Co-Director will help investigators formulate specific aims and research plans that are translational in nature, with realistic and appropriate budgets. Thus, in addition to developing promising research projects for the SPORE program, the Developmental Research Program also will be a major educational activity that will further enhance the initiation and development of innovative translational research concepts in breast cancer. The SPORE Executive Committee will screen proposals for appropriate SPORE qualifications using objective criteria. The selected proposals then will undergo scientific review and prioritization by members of the SPORE External Scientific Advisory Board;final selection of the research projects to be funded will be made on the basis of these reviews. A two-year funding period will be allowed, with allocation of funds for the second year to be made after satisfactory review of a thorough progress report from the awardee. Additional funding may be granted if it is felt that an additional year of work will lead to independent peer-reviewed funding and/or lead to significant enhancement in treatment or prevention of breast cancer. Requests for this additional funding will be very carefully reviewed by the SPORE Executive Committee and External Scientific Advisory Board. As part of our continuing efforts to expand breast cancer research at M.D. Anderson Cancer Center and in anticipation of this SPORE application, developmental research projects were solicited within our institution in early 2004;the five projects considered to be of highest potential and consistent with the translational focus of the SPORE are included here and represent those that will be reviewed for funding consideration to begin in Year 1 of the SPORE program. These projects illustrate the breadth and depth of interest in breast cancer translational research at our institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116199-05
Application #
7906042
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2012-08-31
Budget Start
2009-09-01
Budget End
2012-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$128,742
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Nanos-Webb, A; Bui, T; Karakas, C et al. (2016) PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene 35:2428-40
Jabbour-Leung, Natalie A; Chen, Xian; Bui, Tuyen et al. (2016) Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther 15:593-607
Lucenay, Kimberly S; Doostan, Iman; Karakas, Cansu et al. (2016) Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res 76:2406-18
Gaur, Sanchaika; Wen, Yunfei; Song, Jian H et al. (2015) Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6:29161-77
Wen, Yunfei; Graybill, Whitney S; Previs, Rebecca A et al. (2015) Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21:448-59
Qi, Yuan; Liu, Xiuping; Liu, Chang-Gong et al. (2015) Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS One 10:e0119230
Guan, Xiaoxiang; Liu, Hongliang; Ju, Jingfang et al. (2015) Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ? 55 years. Mol Carcinog 54:281-90
Gutierrez-Rubio, S A; Quintero-Ramos, A; Durán-Cárdenas, A et al. (2015) 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res 14:1250-9
Nodora, Jesse N; Cooper, Renee; Talavera, Gregory A et al. (2015) Acculturation, Behavioral Factors, and Family History of Breast Cancer among Mexican and Mexican-American Women. Womens Health Issues 25:494-500
Wen, Yunfei; Zand, Behrouz; Ozpolat, Bulent et al. (2014) Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7:488-500

Showing the most recent 10 out of 137 publications